Physician profile
Mark Edward Jonas
NPI 1144219957
$7,466.79
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $412 · 2021: $1,109 · 2022: $1,378 · 2023: $2,423 · 2024: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Education: $19.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.85 |
| Education | $19.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,898.84 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $793.97 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $756.51 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $692.60 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $648.26 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $627.66 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $315.05 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $210.57 | 2019-2023 | Dificid |
| Pfizer INC. | $207.65 | 2019-2022 | |
| Qol Medical, LLC | $149.94 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $142.27 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $125.01 | 2021-2024 | Rebyota, Clenpiq |
| Janssen Scientific Affairs, LLC | $124.86 | 2019 | |
| Tosoh Bioscience, INC. | $95.00 | 2019 | |
| Daiichi Sankyo INC. | $80.17 | 2019-2023 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $56.43 | 2020-2023 | Ocaliva |
| Evoke Pharma, INC. | $54.08 | 2021-2023 | Gimoti |
| Allergan, INC. | $51.90 | 2019 | |
| Ucb, INC. | $47.89 | 2019 | |
| Romark Laboratories, Lc | $47.08 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $46.91 | 2023 | Dupixent |
| Alnylam Pharmaceuticals INC. | $45.81 | 2022 | |
| Madrigal Pharmaceuticals | $45.59 | 2024 | Resmetirom |
| Mallinckrodt Hospital Products INC. | $36.76 | 2022-2023 | Terlivaz |
| Celltrion USA INC. | $36.29 | 2023-2024 | Yuflyma, Vegzelma |
| Shionogi INC | $33.49 | 2019 | |
| Lilly USA, LLC | $32.27 | 2024 | Omvoh |
| Dova Pharmaceuticals | $22.53 | 2019 | |
| Genzyme Corporation | $14.91 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.27 | 2024 | Voquezna |
| Novo Nordisk INC | $13.22 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.